FDA To Evaluate Prescribing In Pregnancy With “Mental Modeling” Of Doctors
Executive Summary
An FDA study to monitor prescribing decisions among care physicians who treat pregnant women could help pave the way for a better understanding of how to communicate drug risks in general
You may also be interested in...
Registries Rising: FDA Looking At TNF Inhibitors; AHRQ Updates Standards
The FDA Amendments Act of 2007 gave the agency many new safety powers and the potential for promotional restrictions and post-marketing fines have understandably received much industry attention. But FDA also appears to be drawing upon its beefed-up authority to increase use of a much older, low-tech safety effort: the patient registry
Registries Rising: FDA Looking At TNF Inhibitors; AHRQ Updates Standards
The FDA Amendments Act of 2007 gave the agency many new safety powers and the potential for promotional restrictions and post-marketing fines have understandably received much industry attention. But FDA also appears to be drawing upon its beefed-up authority to increase use of a much older, low-tech safety effort: the patient registry
FDA Risk Communication Strategy May Include Overhaul Of Labeling Language
As FDA assesses its new risk management powers and overall drug safety strategy, it continues to focus on how to revise what has been its primary communications tool for decades - product labeling